Two years after launching with a $350 million debut fund, Chemistry Ventures is signaling that it has no intention of slowing its pace in the crowded AI investment landscape. The firm is currently raising $500 million for its second fund, according to an SEC filing, marking a significant step up in capital deployment for the early-stage investor.

Founded by a trio of venture capital veterans—Mark Goldberg of Index Ventures, Ethan Kurzweil of Bessemer Venture Partners, and Kristina Shen of Andreessen Horowitz—Chemistry was built on the premise of distilling the institutional rigor of legacy firms into a more agile, early-stage vehicle. The firm’s strategy has centered on the infrastructure and application layers of the AI stack, backing companies like Granola, Decagon, and Persona.

The Shift Toward Larger AI Bets

The move to a $500 million vehicle suggests that the firm’s partners believe the window for early-stage AI disruption is widening, not closing. While the initial $350 million fund allowed the team to establish a footprint, this larger pool of capital provides the flexibility to lead larger seed and Series A rounds in a market where valuations for AI-native startups remain stubbornly high.

According to reports, the fund is already oversubscribed, a testament to the firm’s ability to leverage the networks and reputations its founders built at their respective former firms. For limited partners, the appeal lies in the firm’s specific focus: rather than chasing generalist software, Chemistry has leaned into the technical complexity of the AI supply chain.

Portfolio Strategy and Market Positioning

Chemistry’s portfolio reflects a deliberate mix of infrastructure providers and consumer-facing AI applications. By backing companies like Nova Intelligence and Serval, the firm is positioning itself to capture value regardless of which specific AI model eventually wins the underlying platform war.

This approach mirrors the "picks and shovels" strategy that defined the early days of the cloud computing boom. By diversifying across the stack, the firm mitigates the risk of betting on a single model provider while maintaining exposure to the massive capital expenditure cycles currently driving the industry.

Key Takeaways

  • Increased Capital: The $500 million target represents a nearly 43 percent increase over the firm's inaugural $350 million fund.
  • Strategic Focus: Chemistry continues to prioritize early-stage investments in AI infrastructure and application-layer startups.
  • Oversubscribed Demand: Despite a cooling venture market, the firm’s second fund has seen strong interest from limited partners, with a final close expected in the coming weeks.

What This Means for Founders

For early-stage founders, the existence of a larger, well-capitalized fund like Chemistry’s means that the competition for high-quality AI deals will remain fierce. As the firm moves into its second fund, its ability to write larger checks will likely put pressure on smaller seed funds that cannot participate in the follow-on rounds required to keep pace with the compute-heavy needs of AI startups.

The firm’s next major milestone will be the official final close of the fund, which is expected to occur before the end of the current quarter. Once the capital is officially deployed, the focus will shift to whether the firm can maintain its early-stage hit rate as it scales its check sizes and portfolio count.